Wave Life Sciences announces a positive update to the ongoing phase 1b/2a FOCUS-C9 Study which is investigating the use of WVE-004 for people living with C9orf72-associated MND or Frontotemporal Dementia (FTD).The results showed a reduction in a biomarker known as Poly(GP) with low single doses of WVE-004. Further data is expected from the trial throughout 2022. Click here to read the latest news release.
